|Mr. Patrick J. Mahaffy||Co-Founder, CEO, Pres & Exec. Director||1.19M||N/A||1963|
|Dr. Gillian C. Ivers-Read||Co-Founder, Chief Regulatory Officer & Exec. VP of Technical Operations||713.41k||N/A||1954|
|Mr. Daniel W. Muehl||Exec. VP & CFO||691.45k||N/A||1964|
|Mr. Paul Edward Gross||Exec. VP, Gen. Counsel & Sec.||697.38k||N/A||1965|
|Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM||Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance and Chief Medical Officer||760.03k||N/A||1968|
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Clovis Oncology, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 7. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 8; Compensation: 9.